Peptides

Cyprumed and MSD Enter Licensing Agreement for Oral Peptide Therapeutics

MSD receives a non-exclusive license for Cyprumed's drug delivery technology for developing oral peptide therapeutics.

CordenPharma Expands Peptide Manufacturing Platform in Switzerland

Contract development and manufacturing organization (CDMO) CordenPharma has finalized plans to establish a new peptide manufacturing facility in Switzerland located at Getec Park in Muttenz near Basel. This investment is part of the company’s growth initiatives with a more than €1 billion strategic investment in peptide development and manufacturing.

Granules India Buys Swiss CDMO Senn Chemicals

Indian pharmaceutical company Granules India has agreed to acquire Senn Chemicals, a Swiss-based contract development and manufacturing organization (CDMO) specializing in peptides. The closing of the deal, which is subject to certain conditions, is expected to occur in the first half of 2025. Financial details of the transaction were not disclosed.

Ambiopharm Breaks Ground on $28 Million Expansion

Ambiopharm, a US-based pharmaceutical services company specializing in peptide manufacturing, recently announced the groundbreaking of a 70,000-square-foot (6,504 m2) capacity expansion project at its Shanghai manufacturing site. This $28 million (€26.6 million) project reflects the company’s commitment to serving growing global demand and confidence in China’s vital role in the global pharmaceutical supply chain.

SK Pharmteco to Expand Production in South Korea

South Korean contract development and manufacturing organization (CDMO) SK Pharmteco announced a major expansion of its small molecule and peptide production capabilities with a $260 million investment to construct a new facility in Sejong, South Korea.

CordenPharma Completes Upgrade of US Peptide Production Site in Colorado

CDMO CordenPharma, a specialist in active pharmaceutical ingredients (APIs), excipients, drug products and packaging services, inaugurated an increased commercial peptide production capacity with newly-upgraded facilities at its Colorado site in the US, which the company says is the world's largest solid-phase peptide synthesis (SPPS) manufacturing facility.

Bachem Inks $531 Million Peptides Manufacturing Deal

Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has signed another order worth more than 500 million Swiss francs – or $531 million – to supply large volumes of peptides following a joint development project. The identity of the customer has not been disclosed.

Croda Acquires South Korean Biotech Firm

UK specialty chemicals company Croda International has agreed to buy Solus Biotech, a South Korean company specializing in ceramide and phospholipid technologies and with emerging capabilities in natural retinol. The purchase price is about £232 million on a debt-free, cash-free basis.

Ensuring API Supply Capacities for Europe and Beyond

Interview with Karl Rotthier, CEO of the Sanofi spin-off EuroAPI.

Bachem Buys DSM’s Sisslerfeld Site

Swiss peptide and oligonucleotide specialist Bachem has agreed to buy an undeveloped site in Sisslerfeld from DSM. It has completed the purchase of a first plot, with others to follow in the coming years.

Bachem Secures Major Peptide Contracts

Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has announced the signing of two major contracts for supplying large volumes of peptides over the next two years. The orders are worth 25 million and 150 million Swiss francs for 2023 and 2024, respectively.

Expanding Into Oligonucleotides

The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this competitive environment in 2019.

The Importance of Innovation for Future Success

Innovative strength has been a cornerstone of Bachem’s business success since the founding nearly 50 years ago. Günther Loidl, Chief Technology Officer for Bachem Holding, talks about a new innovation management system that will further heighten the importance of innovation in the future.

Innovative Anti-Infectives

Bachem: Anne-Kathrin Stoller to assume CMO position as of 2018

Swiss biochemicals company Bachem announced that Dr. Anne-Kathrin Stoller will succeed Dr. José de Chastonay as Chief Marketing Officer of the organization on January 1, 2018.

Janssen Gains Access to PeptiDream’s Technology

Lonza Sells Belgian Peptides to PolyPeptide

AstraZeneca and Bicycle Therapeutics in Peptides Pact

Trends in Chemical & Pharmaceutical Research

The Possibilities Of Peptides

Modified Peptides

The folded structure of a protein defines its interactions with other molecules. Selective binding ligands could be, e.g., other proteins or peptides. A natural protein consists exclusively of L-amino acids and glycine, and its folded structure is chiral.

Fujifilm Holdings to Acquire Cellular Dynamics

Bachem acquires American Peptide Company

Bachem and GlyTech announce co-promotion agreement

Partner for Peptides

Lonza’s Corporate Overhaul

Chemical Distribution: Three Attractive Markets

Fine Chemicals: The Top 10

Sustainability All Along The Value Chain

Roche Signs Up to $1.1 Billion Drug Deal with Aileron